Orum Therapeutics and Vertex Pharmaceuticals have agreed to develop novel targeted conditioning agents for gene editing using Orum’s Dual-Precision Targeted Protein Degradation (TPD²) technology.
Vertex can exclusively license and commercialize DACs developed with Orum’s TPD² technology for up to three targets. In return, Orum will receive an upfront payment of $15 million and potential option payments, milestones, and tiered royalties totaling up to $310 million per target.
Orum’s TPD² technology is a platform for targeting specific proteins for degradation. It can potentially create a new class of drugs called degrader-antibody conjugates (DACs), which could treat various diseases by targeting and degrading specific proteins.
Vertex is a leader in gene editing, having received the first FDA approval for a CRISPR/Cas9 gene-edited therapy. Orum’s TPD² technology will enable Vertex to explore novel conditioning agents that could enhance the efficacy and safety of gene editing therapies.
This collaboration combines Orum’s expertise in targeted protein degradation with Vertex’s strength in gene editing. It aims to pave the way for novel treatment options for patients in a new therapeutic area.
Vertex is a global biotechnology company that develops innovative medicines for serious diseases. Orum Therapeutics is a clinical-stage biotechnology company specializing in degrader-antibody conjugates for protein degradation.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
